Botox (therapeutic and cosmetic)
E697100
botulinum toxin type A preparation
cosmetic treatment
injectable medication
therapeutic biologic product
Botox (therapeutic and cosmetic) is a widely used botulinum toxin–based injectable treatment employed both medically to manage conditions like muscle spasticity and migraines and cosmetically to reduce the appearance of facial wrinkles.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Botox (therapeutic and cosmetic) canonical | 1 |
Statements (51)
| Predicate | Object |
|---|---|
| instanceOf |
botulinum toxin type A preparation
ⓘ
cosmetic treatment ⓘ injectable medication ⓘ therapeutic biologic product ⓘ |
| activeIngredient | onabotulinumtoxinA ⓘ |
| boxedWarning | toxin effects may spread beyond injection site ⓘ |
| commonAdverseEffect |
headache
ⓘ
injection site pain ⓘ localized muscle weakness ⓘ |
| contraindication |
infection at proposed injection site
ⓘ
known hypersensitivity to botulinum toxin ⓘ |
| derivedFrom | Clostridium botulinum toxin type A ⓘ |
| durationOfEffect | typically 3 to 4 months ⓘ |
| effect |
reduction of dynamic wrinkles
ⓘ
temporary muscle relaxation ⓘ |
| hasCosmeticUse |
facial wrinkle reduction
ⓘ
treatment of forehead lines ⓘ treatment of glabellar lines ⓘ treatment of lateral canthal lines ⓘ |
| hasMedicalUse |
treatment of axillary hyperhidrosis
ⓘ
treatment of blepharospasm ⓘ treatment of cervical dystonia ⓘ treatment of chronic migraine ⓘ treatment of lower limb spasticity ⓘ treatment of muscle spasticity ⓘ treatment of overactive bladder ⓘ treatment of strabismus ⓘ treatment of upper limb spasticity ⓘ treatment of urinary incontinence due to neurologic conditions ⓘ |
| hasPrimaryUse | reduction of facial wrinkles ⓘ |
| hasRegulatoryStatus | prescription only medicine in many countries ⓘ |
| hasRouteOfAdministration |
intradermal injection
ⓘ
intradetrusor injection ⓘ intramuscular injection ⓘ |
| isAdministeredBy |
licensed healthcare professional
ⓘ
nurse practitioner ⓘ physician ⓘ physician assistant ⓘ |
| isAdministeredIn | outpatient setting ⓘ |
| isApprovedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| isManufacturedBy | Allergan NERFINISHED ⓘ |
| isTradeNameOf | onabotulinumtoxinA NERFINISHED ⓘ |
| isUsedFor | both therapeutic and cosmetic indications ⓘ |
| mechanismOfAction |
inhibition of acetylcholine release at neuromuscular junctions
ⓘ
temporary chemodenervation of muscles ⓘ |
| onsetOfAction | typically within 3 to 7 days ⓘ |
| peakEffectTime | about 2 weeks after injection ⓘ |
| requires |
prescription
ⓘ
repeated treatments to maintain effect ⓘ |
| seriousAdverseEffect |
dysphagia
ⓘ
respiratory compromise ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.